Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sonova Holding AG (OTC: SONVY) reported stronger-than-expected earnings for fiscal 2025-26, posting normalized EBITA of CHF 811.2 million, above analyst expectations of CHF 780.8 million. The Swiss hearing solutions company also achieved a normalized EBITA margin of 22.5%, outperforming the consensus estimate of 21.6%. Annual sales reached CHF 3.61 billion, matching market forecasts.
The company said foreign exchange headwinds weighed on reported figures, with reported EBITA declining 5.8% year-over-year to CHF 724.2 million. Currency fluctuations reduced normalized EBITA by CHF 106.5 million and cut margins by 1.5 percentage points.
CEO Eric Bernard stated that Sonova delivered results in line with company guidance while continuing to outperform the broader hearing care market. Group sales were nearly flat in Swiss francs but increased 5.9% in local currencies, supported by 5.4% organic growth and additional contributions from acquisitions.
Sonova’s Hearing Instruments division remained the key growth driver. Segment sales climbed 7.5% in local currencies to CHF 3.35 billion, while normalized EBITA rose 20.6% to CHF 793.7 million. The segment achieved a strong 23.7% EBITA margin, highlighting robust demand for hearing aid products.
However, the Cochlear Implants segment faced significant pressure. Sales dropped 11.1% in local currencies to CHF 252.1 million, missing analyst expectations. The company blamed weaker performance in China after the implementation of volume-based procurement measures. Segment EBITA fell sharply to CHF 17.2 million, with margins shrinking to 6.8%.
Sonova also announced that losses tied to its discontinued Consumer Hearing business reached CHF 106.5 million as the company moves forward with plans to divest the unit.
Looking ahead, Sonova forecasts 2026-27 sales growth of 5% to 8% and core EBIT growth of 7% to 10% at constant exchange rates. The board also proposed a record dividend of CHF 4.70 per share, up 7% from last year.
